COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits. All Patients – Very Important: Regardless of vaccination status. If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing. More Information-PLEASE CLICK HERE
Getting a diagnosis of cancer is the most challenging thing any patient and family will have to go through. My job is to provide the most comprehensive options for patients, with state-of-the-art care and compassion.
Work and Credentials:
Primary Location
Position
Medical Oncologist
Board Certification
Medical Oncology and Internal Medicine
Fellowship
Johns Hopkins Hospital, Medical Oncology
Internship
Hospital of the University of Pennsylvania
Residency
Hospital of the University of Pennsylvania
Medical School
New York University School of Medicine
College
Harvard University
Alexander I Spira, MD, PhD, FACP
Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins
Dr. Alexander Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.
As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.
Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.
Physician Videos:
Physician Reviews:
Dr Spira is probably one of the best oncologists. His runs so many clinical trials and extremely knowledgeable. That really shows how passionate he is in finding effective treatments for cancer patients. I am very lucky to have him as my oncologist.
Great job: knowledgeable, informative, and a human touch,(apposed to robotic). He and his staff are outstanding.
Dr Alex Spira is "fully engaged & committed", a truly Top Notch Medical Professional at Virginia Cancer Specialists (VCS). He is well prepared, able to communicate in a caring but being respectful to his Patients, while building "trust" to improve and advance the health & life of the VCS Patients ! Plus, based on our recent VCS visits, Dr. Spira's and the VCS Teams project a true desire to provide the "Best Quality Care for Patients". On that note, I have personally noted, Dr Spira's "day to day" interactions with his Dr.'s, RN Nurses, VCS Teams and Patients. Dr Alex Spira demonstrates "Leadership & Quality Care to Patients", by building the VCS Medical "bench strength" by ensuring everyone is cross trained to ensure quality care to Patients from all the VCS Team of Specialist, that's "Team Work" ! My Care Giver (my wife) and I are proud to be a Patent's and be part of VCS, at this time of my life, God Bless, Thank You to all Medical "Professionals" at VCS !
Dr. Spira was professional, knowledgeable and informative. Both the Doctor and his staff were approachable, engaging and friendly. Both my wife and I found our experience with Dr. Spira to be quite positive.
Dr Spira has been treating my cancer for eight years. He is competent and caring. I am always happy to see him, and him me. He is a brilliant scientist who is on top of his field.
Dr. Spira and all his staff at VCS are first rate as they really try their best in providing the best healthcare possible. Dr. Spira is a most distinguished and commendable oncologist. He is open to patient"s questions all the time and provide answers that are comforting and easily understood. I would highly recommend this facility.
Physician Publications
April 8, 2022
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
Read MoreJanuary 29, 2021
Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer
Read MoreJanuary 29, 2021
Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC
Read MoreMore Publications by Alexander I Spira, MD, PhD, FACP
September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cance
Read MoreAugust 11, 2020
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Read MoreJune 7, 2020
Camidanlumab Tesirine, an Antibody-Drug Conjugate, in Relapsed/Refractory CD25-positive Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia: A Phase I Study
Read MoreApril 7, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasThe ANNOUNCE Randomized Clinical Trial
Read MoreOctober 1, 2019
A review of canakinumab and its therapeutic potential for non-small cell lung cancer.
Read MoreAugust 1, 2019
Detection of NRG1 Gene Fusions in Solid Tumors.
Read MoreAugust 1, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Read MoreSeptember 25, 2018
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
Read MoreMarch 9, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Read MoreSeptember 14, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Read MoreJune 3, 2013
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.
Read MoreFebruary 1, 2013
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
Read MoreJanuary 2, 2013
Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma
Read MoreJune 1, 2012
Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer
Read MoreApril 16, 2012
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Read MoreJanuary 1, 2012
Clinical trial design in the age of molecular profiling.
Read MoreSeptember 8, 2011
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Read MoreJune 1, 2011
Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients
Read MoreJune 1, 2011
Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).
Read MoreJune 1, 2011
Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
Read MoreDecember 4, 2010
Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.
Read MoreDecember 1, 2010
Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.
Read MoreDecember 3, 2009
Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations.
Read MoreDecember 1, 2009
Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Read MoreJanuary 22, 2004
Multidisciplinary Management of Lung Cancer
Read MoreJanuary 1, 2002
The use of Chemotherapy in Soft Tissue Sarcomas
Read MoreClinical Trials (148)
Clinical Trial RBS2418
A First-in-Human, Phase 1a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizuamab in Subjects with Advanced Unresectable, Recurrent Metastatic Tumors.
Clinical Trial BBP-398
A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation
Clinical Trial BIO-106
A Phase 1/2 Study of BIO-106 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Cancers (Starbridge-1)
Clinical Trial CF33-hNIS
A Phase 1, Dose Escalation, Safety, and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors
Clinical Trial TNG908-C101
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-Tumor Activity of TNG908 in Patients with MTAP-Deleted Advanced or Metatstatic Solid Tumors.
Clinical Trial PRT2527-01
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors
All Clinical Trials for Alexander I Spira, MD, PhD, FACP
Clinical Trial RBS2418
A First-in-Human, Phase 1a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizuamab in Subjects with Advanced Unresectable, Recurrent Metastatic Tumors.
Clinical Trial BBP-398
A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation
Clinical Trial BIO-106
A Phase 1/2 Study of BIO-106 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Cancers (Starbridge-1)
Clinical Trial CF33-hNIS
A Phase 1, Dose Escalation, Safety, and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors
Locations:
Clinical Trial TNG908-C101
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-Tumor Activity of TNG908 in Patients with MTAP-Deleted Advanced or Metatstatic Solid Tumors.
Clinical Trial PRT2527-01
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors
Clinical Trial AN4005
An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors
Clinical Trial NUV-422-04
A Phase 1b/2 Safety and Efficacy Study of NUV-422 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Trial NUV-422-03
Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive Epidermal Growth Factor Receptor2-Negative (HR+ HER2-) Advanced Breast Cancer
Clinical Trial SET-101
A Phase 1/1b, Open-Label Multi Center Two Part Study of SETD2 Inhibitor EZM414 in Subjects with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical Trial PY314-1-101
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Clinical Trial BDTX-1535
A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer
Clinical Trial BLU-451-1
A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations
Clinical Trial INBRX-209
A Randomized, Blinded, Placebo-Controlled, Phase 2 Study of INBRX-109 in Unrsectable or Metastatic Conventional Chondrosarcoma
Locations:
ClinicalTrials.gov ID:
NCT04950075
ClinicalTrials.gov Link:
Clinical Trial CLN-619-001
A Phase 1 Dose Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Clinical Trial Onc-392-001
Safety, Pharmacokinetics, and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase 1A/1B Study
Clinical Trial BB1701
A First-in-Human, Open Label, Multiple Dose, Dose Escalation, and Cohort Expansion Phase I Study to Investigate the Safety, Tolerablity, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Clinical Trial D9077C00001
A Phase 2 Open-Label, Multicenter Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II-IIIA) NSCLC
ClinicalTrials.gov ID:
NCT05061550
ClinicalTrials.gov Link:
Clinical Trial CINC280AUS12
A Phase 2 Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification
ClinicalTrials.gov ID:
NCT04926831
ClinicalTrials.gov Link:
Clinical Trial USOR 21320
A Phase 1/2 Open-Label Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutated, Metastatic NSCLC Who Have Progressed After Treatment with Osimertinib
Clinical Trial TTI-621-03
A Phase 1/2 Study of TTI-621 in Combination with Doxorubacin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma
Clinical Trial USOR 21321
A Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory Gliomas and Solid Tumors
Clinical Trial USOR 21281
A Phase 1b, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors
Clinical Trial INBRX105
An Open-Label, Multicenter, First-in-Human Dose Escalation, Phase 1 Study of INBRX-105 and INBRX-105 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Clinical Trial D910GC00001
A Randomized, Double Blind, Placebo-Controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy in Patients with Resectable Gastric and GE Junction Cancer
Clinical Trial HFB-301001-01
A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients with Advanced Solid Tumors
Locations:
Clinical Trial ASP1570
A Phase 1 Study of ASP1570 in Participants with Solid Tumors
Clinical Trial ASP7517
A Phase 1/2, Open-Label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Known to Express WT1 Antigen
Clinical Trial PRJ1-3024
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Clinical Trial ES002023-1001
An Open-Label, Mulitcenter, First-in-Human, Dose Escalation, Phase 1 Study of ES002023 in Patients with Locally Advanced or Metastatic Solid Tumors
Clinical Trial IMM2902-101
A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors
Clinical Trial M21-404
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects with Advanced Solid Tumors
Clinical Trial ZB131-101
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likley to Express CSP
Clinical Trial HFB200301-01
A Phase 1, Open-Label, Multi-Center, Dose Escalation and expansion study of HFB200301 (TNFR2 Agonist Antibody) in Adult Patients with Advanced Solid Tumors
Locations:
Clinical Trial HBI-2376-101
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Clinical Trial NVL-520-01
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and other Solid Tumors
Clinical Trial CTIV1708
A Phase 1/2 Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 when Administered via Intratumoral Injection as a Single Agent and in Combination with Intravenous Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors.
Clinical Trial BGB-A317-A1217-301
A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiation Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus CCRT Followed by Tislelizumab Versus CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable NSCLC
Clinical Trial STRO-002-GM2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).
Clinical Trial STK-012-101
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors
Clinical Trial M21-410
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab
Clinical Trial RLY-2608-101
A First-in-Human Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Clinical Trial RTX-224-01
A Phase 1/2 Study of RTX-224 for the Treatment of Patients with Advanced Solid Tumors.
Clinical Trial 516-010
A Two-Cohort, Two-Part, Phase 1, Multicenter, Open-Label, Fixed-Sequence, Drug-Drug Interaction with QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Tumors.
Clinical Trial BLU-701-1101
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Clinical Trial NBF-006
A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.
Clinical Trial SALA-002-EW16
A Phase I Trial of LSD1 Inhibitor Seclidemstat (SP-2577) with and without Topetecan and Cyclophosphamide in Patients with Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Clinical Trial EFT226-0002
A Phase 1/2 Open Label, Sequential Group, Dose Escalation and Cohort Expansion Sutdy Evaluating the Safety, PK, PD and Antitumor Activity of eFT226 in Subjects with Selected Advanced Solid Tumors
Clinical Trial MPH313-1-02
A Phase 1b/2 Open Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Locations:
ClinicalTrials.gov ID:
NCT04751198
Clinical Trial LOXO-RAS-20001
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutated Advanced Solid Tumors
Clinical Trial MVR-T3011-003
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered via Intravenous Infusion as a Single Agent and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors
Clinical Trial GO-007
A Screening Study for the Selection of Patients for Clinical Studies Targeting Tumor-Specific Antigens (Non-Interventional)
ClinicalTrials.gov ID:
NCT03953235
ClinicalTrials.gov Link:
Clinical Trial VX15-2503-12
A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent, or Metastatic Squamous Cell Cancer of the Head and Neck
Clinical Trial TPX-0005-13
A Phase 1B/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS Mutated Advanced Solid Tumors
Clinical Trial FW-2020-1
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumors.
Locations:
ClinicalTrials.gov ID:
NCT04731467
Clinical Trial KZR-261-101
A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects with Advanced Solid Malignancies
Clinical Trial ERAS-007-03
Phase 1b/2 Study of Agents Targeting the Mitogen Activated Protein Kinase Pathway in Patients with Advanced GI Malignancies
Clinical Trial USOR 21400
A Phase 2 Clinical Study of TJ004309 in Combination with Atezolizumab in Patients with Advanced or Mets Ovarian Cancer and Selected Advanced Solid Tumors.
ClinicalTrials.gov ID:
NCT05001347
ClinicalTrials.gov Link:
Clinical Trial MRG004A-001
“An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess
the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in
Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors”
Clinical Trial AVB500-PC-005
A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nabpaclitaxel
and Gemcitabine in Patients with Locally Advanced
or Metastatic Pancreatic Adenocarcinoma
Clinical Trial C4401001
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE
SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS,
AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED
OR METASTATIC TUMORS
Clinical Trial 20291
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects with Advanced Solid Tumors with KRAS G12C Mutation **MANY SUBPROTOCOLS FOR THIS TRIAL**
Clinical Trial 20289
A Phase I Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Clinical Trial 20305
An Open-Label, Phase 1b, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Efficacy of the Aryl Hydocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Combination with Pembrolizumab in Participants with Advanced Tumors
Clinical Trial 18020
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Clinical Trial TWT-101
A First in Human, Phase 1/2 Study of CFI-402411, Hematopoeitic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advnanced Solid Malignancies
Clinical Trial TTX-030-002
A Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors
Clinical Trial TPX-0022-01
A Phase I, Open-Label, Multicenter, First in Human Study of the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of TPX-0022, A Novel MET/CSF1R/SRC Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations I MET
Clinical Trial RTX-24-01
Open-Label, Multicenter, First in Human Phase 1/2 Study of RTX-240 for the Treatment of Patients with Relapsed/Refractory or Locally Advanced Solid Tumors
Clinical Trial PEN-866-001
A Phase 1/2a, Open-Label, Mutlicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Patients with Advanced Solidy Malignancies
Clinical Trial DF6002-001
A Phase 1/2, First in Human, Multi-Part, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Clinical Trial TPX-0046-01
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects with Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Clinical Trial ORIC-101-18101
An Open-Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Clinical Trial M19-037
A Phase I, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors
Clinical Trial NB-ND021 (NM21-1480)-101
Phase 1/2 Study of NM21-1480 (Anti-PD-L1/Anti-4-1BB/Anti-HAS Tri-Specific Antibody) in Adults with Advanced Solid Tumors
Clinical Trial JAB-3312-1003
A Phase 1/2a, Multi-center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB3312 in Combination with Pembrolizumab or Binimetinib in Adults with Advanced Solid Tumors
Clinical Trial I-MAB
A Phase I Study of TJ210001 Administered in Subjects with Relapsed or Refractory Advanced Solid Tumors
Clinical Trial CPO-100-US-101
A Phase I, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adults with Advanced Solid Tumors
Clinical Trial D967VC00001
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors
Clinical Trial D976MC00001
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Unresectable and or Mets Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology
Clinical Trial 20383
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Everolimus in Subjects with Advanced Solid Tumors with KRAS G12C Mutation
Clinical Trial KN 8701
A Phase 1/1b Open-Label, Multicenter, Two-Part Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-8701 in Subjects with BRAF Mutation Positive Solid Tumors
Clinical Trial TCTLR-101
Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Clinical Trial D6185C00001
An Open-Label, Multi-Drug, Biomarker-Directed, Multicenter Phase II Umbrella Study in Patients with NSCLC, Who Progressed on and Anti-PD-1/PD-L1 Containing Therapy
Clinical Trial AB154CSP0002
A Phase II Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line NSCLC
ClinicalTrials.gov ID:
NCT04262856
ClinicalTrials.gov Link:
Clinical Trial BGB-A317-A1217-302
A Phase III, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination with Tislelizumab Compared to Pembrolizumab in Patients with Previously Untreated, PD-L1 Selected, and Locally Advanced, Unresectable or Metastatic NSCLC
ClinicalTrials.gov ID:
NCT04746924
ClinicalTrials.gov Link:
Clinical Trial D910MC00001
Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy.
Locations:
Clinical Trial 20139
A Phase III, Randomized, Controlled, Multi-Center, 3 Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SOC Chemo Alone for the Treatment of Patients with EGFR Positive, Resectable NSCLC
Clinical Trial D910LC00001
A Phase III, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-Based Chemotherapy in Completely Resected Stage II-III NSCLC
Clinical Trial 21177
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 in Patients with Solid Tumors Likely to Express NaPi2b
Clinical Trial ACT16146
Randomized, Open-Label Phase II Study of SAR408701 Combined with Pembrolizumab and Pembrolizumab Alone in Patients with CEACAM5 and PD-L1 Positive Advanced/Metastatic Non-Squamous NSCLC.
ClinicalTrials.gov ID:
NCT04524689
ClinicalTrials.gov Link:
Clinical Trial 20270
Phase II Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced NSCLC with KRAS G12C Mutation
ClinicalTrials.gov ID:
NCT04613596
ClinicalTrials.gov Link:
Clinical Trial 20384
A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG510 (pINN Sotorasib) in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced NSCLC with KRAS G12C Mutation
Locations:
ClinicalTrials.gov ID:
NCT04185883
ClinicalTrials.gov Link:
Clinical Trial U31402-A-U103
A Phase I Open-Label Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Subjects with Locally Advanced or Mets EGFR-Mutated NSCLC
Clinical Trial 61186372EDI1001
Phase I, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced NSCLC
Clinical Trial TPX-0131-01
Phase I/II Study of TPX-0131, A Novel Oral ALK TKI in Subjects with ALK+ Advanced or Metastatic NSCLC
Clinical Trial KL 264-01
A Phase I-II, First in Human Study of SKB264 in Patients with Locally Advanced Unresectable and Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Clinical Trial 20414
An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab in Subjects with Advanced Solid Tumors
Clinical Trial MRTX849-001
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C
Clinical Trial PCS6422G1-01
A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors
ClinicalTrials.gov ID:
NCT04861987
ClinicalTrials.gov Link:
Clinical Trial 20310
A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS G12C
Clinical Trial 21194
A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with MVASI and FOLFIRI and in Combination with MVASI and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS G12C Mutation
Locations:
ClinicalTrials.gov ID:
NCT04190135
Clinical Trial RTX-321-01
Phase 1 Trial of RTX-321 for Patients That Are HLA-A+ with Persistent, Recurrent, or Metastatic, Unresectable HPV 16+ Cancers
Locations:
Clinical Trial CTMX-2009-002
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR Positive/HER2 Negative Breast Cancer and of CX2009 as Monotherapy and in Combination with CX-072 for Advanced Triple Negative Breast Cancer
Clinical Trial DS1062-A-U301
Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Clinical Trial D967LC00001
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer
Clinical Trial 20344
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Clinical Trial 20381
Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)
ClinicalTrials.gov ID:
none
Clinical Trial 20331
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov ID:
NCT04620330
ClinicalTrials.gov Link:
Clinical Trial 18194
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Clinical Trial 20249
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
ClinicalTrials.gov ID:
NCT04538664
ClinicalTrials.gov Link:
Clinical Trial CLN-081-001
A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Clinical Trial ZWI-ZW49-101
Clinical Trial PLX124-03
A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Clinical Trial 73841937NSC1001
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Clinical Trial 19211
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) (D9106C00001)
ClinicalTrials.gov ID:
NCT03800134
ClinicalTrials.gov Link:
Clinical Trial RTX-240-01
PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors.
Clinical Trial 20137
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)
ClinicalTrials.gov ID:
NCT04513925
ClinicalTrials.gov Link:
Clinical Trial M19-611
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Clinical Trial APG-115-US-002
Clinical Trial KL26401
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies
Clinical Trial 19043
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)
Clinical Trial 19082
A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)
Clinical Trial TPX-005-001
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Locations:
ClinicalTrials.gov ID:
NCT03093116
ClinicalTrials.gov Link:
Clinical Trial PSB205
A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/ Refractory Solid Tumors
Clinical Trial ASTX295-01
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
Clinical Trial 849-001
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Clinical Trial 14059
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Locations:
ClinicalTrials.gov ID:
NCT3379428
Clinical Trial 101-18101
An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Clinical Trial GO-005
A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors
Clinical Trial M14-239
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Clinical Trial C2321001
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Clinical Trial LOXO-RET-17001
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001
Clinical Trial CP-MGC018-01
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors
Clinical Trial AO-176-101
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Clinical Trial GO-004
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors
Clinical Trial AMXT1501-101A
PHASE I DOSE-FINDING, SAFETY STUDY OF ORAL AMXT 1501 DICAPRATE AND DIFLUOROMETHYLORNITHINE (DFMO) IN PATIENTS WITH ADVANCED SOLID TUMORS
Clinical Trial Janssen 61186372EDI10051
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Clinical Trial GO-003
An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer
Locations:
Clinical Trial 17-167
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
ClinicalTrials.gov ID:
NCT03447769
ClinicalTrials.gov Link:
Clinical Trial CTMX-M-2029-001
A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)
Clinical Trial 18-020
A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)
Clinical Trial Astex ASTX029
Study of ASTX029 in Subjects With Advanced Solid Tumors
Clinical Trial STRO-001-BCM1
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Clinical Trial DS1062-A-J101
First-in-human Study of DS-1062a for Advanced Solid Tumors
Clinical Trial Tesaro 4020-01-001
A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Trial R3767-ONC-1613
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Clinical Trial M14-237
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors
